Urogen Pharma (NASDAQ:URGN) General Counsel Sells $64,618.26 in Stock

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Smith sold 1,519 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total transaction of $64,618.26. Following the transaction, the general counsel owned 53,141 shares of the company’s stock, valued at $2,260,618.14. This trade represents a 2.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Urogen Pharma Trading Up 0.2%

Shares of NASDAQ:URGN opened at $42.31 on Friday. Urogen Pharma has a 52 week low of $15.86 and a 52 week high of $50.81. The company’s 50 day moving average is $43.33 and its two-hundred day moving average is $31.53. The company has a market cap of $2.07 billion, a PE ratio of -21.37 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. As a group, equities research analysts expect that Urogen Pharma will post -0.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on URGN. Oppenheimer lifted their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Jefferies Financial Group reissued a “buy” rating and set a $56.00 target price on shares of Urogen Pharma in a research report on Thursday. HC Wainwright boosted their target price on Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. TD Cowen upped their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Guggenheim increased their price target on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Urogen Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $52.38.

Hedge Funds Weigh In On Urogen Pharma

Several large investors have recently bought and sold shares of URGN. Opaleye Management Inc. increased its position in shares of Urogen Pharma by 0.7% during the second quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock worth $52,992,000 after purchasing an additional 9,996 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Urogen Pharma in the 2nd quarter valued at about $603,000. Squarepoint Ops LLC acquired a new stake in shares of Urogen Pharma in the 2nd quarter valued at about $431,000. California State Teachers Retirement System grew its stake in Urogen Pharma by 4,168.7% during the 2nd quarter. California State Teachers Retirement System now owns 1,654,123 shares of the company’s stock worth $60,872,000 after buying an additional 1,615,373 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in Urogen Pharma by 15.1% during the 2nd quarter. Wellington Management Group LLP now owns 115,362 shares of the company’s stock worth $4,245,000 after buying an additional 15,147 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.